By Jason Derry —

Organon and MRC Technology have announced an intent to collaborate in the development of a humanized antibody for treating various cancers.  Under the agreement, MRC will use its CDR grafting technology to generate a humanized antibody based on one of
Organon’s murine antibodies as a candidate for clinical development.  MRC will receive milestone payments and royalties based on sales of a commercialized product.  Organon is a biopharmaceutical company that is expanding its interest in biotechnology to the fields of immunology and oncology.  MRC Technology performs technology transfer activities for the UK Medical Research Council, and provides chemical and biology tools to assist pharmaceutical and biotech companies in drug discovery.

For additional information regarding this collaboration, please see:

• MRC Technology’s press release

Jason Derry, Ph.D., who graduated with honors from DePaul University
College of Law, is a molecular biologist and founding author of Patent Docs.